Table 1a. Patients' characteristics.
|
Patients treated with DG or DC
|
||
|---|---|---|
| Number | % | |
| Gender | ||
| Male | 106 | 88 |
| Female | 25 | 12 |
| Age (years) | ||
| Median | 60 | |
| Range | 37–78 | |
| Performance status (ECOG) | ||
| 0 | 67 | 51 |
| 1 | 52 | 40 |
| 2 | 12 | 9 |
| Stage | ||
| IIIB (wet) | 35 | 27 |
| IV | 96 | 73 |
| Histology | ||
| Adenocarcinoma | 68 | 52 |
| Squamous | 56 | 43 |
| Other | 7 | 5 |
| Regimen | ||
| Docetaxel cisplatin | 64 | 49 |
| Docetaxel Gemcitabine | 67 | 51 |
| Response rate (CR+PR) | 40 | 30 |
| PFS (months, 95% CI) | 4.2 (2.7–5.7) | |
| Median OS (months, 95% CI) | 11.1 (9.7–14.6) | |
Abbreviations: CR=complete response; PR=partial response; PFS=progression-free survival; OS=overall survival; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; DG=docetaxel and gemcitabine; DC=docetaxel and cisplatin.